References
- Klein D. C., Raisz L. G. Prostaglandins: Stimulation of bone resorption in tissue culture. Endocrinology 1970; 86: 1436–1440
- Flanagan A. M., Chambers T. J. Stimulation of bone nodule formation in vitro by prostaglandin E1and E2. Endocrinology 1992; 130: 443–448
- Weinreb M., Suponitzky L, Keila S. Systemic administration of an anabolic dose of PGE2in young rats increases the osteogenic capacity of bone marrow. Bone 1997; 20: 521–526
- Li X. J., Jee S. S., Li Y. L., Buckendahl P. P. Transient effects of subcutaneously administrated prostaglandin E2on cancellous and cortical bone in young adult dogs. Bone. 1990; 11: 353–364
- Norrdin R. W., Jee WSS, High WB. The role of prostaglandins in bone in vivo. Prostaglandin Leukotriene Ess Fatty Acid 1990; 41: 139–149
- Miller S. C., Marks S. C. Local stimulation of new bone formation by Prostaglandin E1: Quantitative histomorphometry and comparison of delivery by minipumps and controlled-release pellets. Bone 1993; 14: 143–151
- Takahashi M., Wehrli F. W., Wehrli S. L., Hwang S. N., Lundy M. W., Hartke J., Borah B. Effect of prostaglandin and bisphosphonate on cancellous bone volume and structure in the ovariectomized rat studied by quantitative three-dimensional nuclear magnetic resonance microscopy. J Bone Miner Res 1999; 14: 680–689
- Parfitt A. M., Simon L. S., Villanueva A. R., Simon S. M. Procollagen type I carboxy terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987; 2: 427–436
- Editorial. Pyridinium crosslinks as markers of bone resorption. Lancet 1992; 340: 278–279
- Eriksen E. F., Charles P., Melsen F., Mosekilde L., Risteli L., Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127–132
- Ueda K., Saito A, Nakano H., Aoshima M., Yokota M., Muraoka R., Iwaya T. Cortical hyperostosis following long-term administration of prostaglandin El in infants with cyanotic congenital heart disease. J Pediatr 1980; 97: 834–836
- Sone K., Tashiro M., Fujinaga T., Tomomasa T., Tokuyama K., Kurourne T. Long-term low-dose prostaglandin E1administration. J Pediatr 1980; 97: 866–867
- Toyota T., Hirata Y., Ikeda Y., Matsuoka K., Sakuma Mizushima A. Lipo- PGE1, a new lipid-encapsulated preparation of prostaglandin El: Placebo- and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins 1993; 46: 453–468
- Ringel R. E., Brenner J. I., Haney P. J., Bums J. E., Moulton A. L., Berman M. A. Prostaglandin-induced periostitis: A complication of long-term PGE1infusion in an infant with congenital heart disease. Radiology 1982; 142: 657–658
- Rowley R. F., Laeson J. P. Case report 701: Prostaglandin El (PGE1) periostitis. Skeletal Radiol 1991; 20: 617–619
- Kaufman M. B., El-Chaar GM. Bone and tissue changes following prostaglandin therapy in neonates. Ann Pharmacother 1996; 30: 269–274
- Faye-Petersen O. M., Johnson W. H., Carlo W. A., Hedlund G. L., Pacifico A. D., Blair H. C. Prostaglandin E1-induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanism. Pediatr Pathol Lab Med 1996; 16: 489–507
- Drvaric D. M., Parks W. J., Wyly B., Dooley K. J., Plauth W. H., Schmitt E. W. Prostaglandin-induced hyperostosis. Clin Orth and Rel Res 1989; 246: 300–304
- Karen W. D., Emery J., Peabody J. Cortical hyperostosis: A complication of prolonged prostaglandin infusion in infants awaiting cardiac transplantation. Pediatrics 1994; 93: 417–420